Spitalul Clinic De Psihiatrie Si Neurologie Brasov — Clinical Trial Site

17 Registered trials

12 Currently recruiting

Organisation

Spitalul Clinic De Psihiatrie Si Neurologie Brasov

Location

Brasov, Romania

Identifier

ORG-100043838

Address

Strada Prundului 7-9, 500123, Romania

Departments

1903: Neurology
Department of Medical Neurology
N/A
Neurology
Psihiatrie
Psihiatrie Clinica III
Psihiatrie I
Psihiatrie II
Psihiatry
Psychiatry
Psychiatry II Clinical Department
Psychiatry III Clinical Department
Sectia Neurologie II
Sectia Psihiatrie II
Sectia Psihiatrie I
Sectia Psihiatrie II

Clinical trials at this site (17)

Search interface

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 BP-I mania or mania with mixed features 5 2026-03-02
Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting

2025-521216-19-00 Schizophrenia 5 2025-12-10
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520195-94-00 BP-I mania or mania with mixed features 5 2025-09-25
Evaluation of NBI-1117568 in Inpatient Adults with Schizophrenia Recruiting

2025-521215-39-00 Schizophrenia 5 2025-12-08
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A phase 3 trial of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia Recruiting

2022-500583-36-00 Acute Schizophrenia 5 2024-07-01
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 4 2025-07-17
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label… Ended

2022-503006-20-00 Acutely Psychotic Patients with Schizophrenia 10